Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will host a virtual R&D Day on November 19, 2021, from 8:30 am to 1:15 pm ET, featuring presentations by senior leaders and guest speakers. The event will be accessible via the Company’s website, www.alnylam.com, with a replay available within 48 hours. Alnylam is a pioneering company in RNA interference (RNAi) therapeutics, focused on transforming the treatment of rare and chronic diseases.
Alnylam Pharmaceuticals has announced the start of the KARDIA-2 Phase 2 study, assessing zilebesiran, an investigational RNAi therapeutic for hypertension management. This global trial will enroll 800 adults whose blood pressure is inadequately controlled by existing medications. The primary endpoint focuses on changes in 24-hour mean systolic blood pressure after three months. The study aims to address the rising prevalence of hypertension, projected to increase by 20% by 2025, highlighting Alnylam's commitment to innovative therapies for unmet needs in hypertension.
Alnylam Pharmaceuticals announced positive results from the ILLUMINATE-C Phase 3 study of lumasiran for treating advanced primary hyperoxaluria type 1 (PH1). This RNAi therapeutic showed significant plasma oxalate reductions in patients with chronic kidney disease, achieving decreases of 33% and 42% in two patient cohorts. These results highlight its efficacy in reducing oxalate levels, essential for preventing complications like systemic oxalosis. Moreover, lumasiran had an acceptable safety profile, with mild injection site reactions being the most common adverse event.
Summary not available.
Alnylam Pharmaceuticals reported a significant Q3 2021 revenue of $167 million for its products ONPATTRO, GIVLAARI, and OXLUMO. The company highlighted promising 18-month results from the HELIOS-A Phase 3 study of vutrisiran in patients with hATTR amyloidosis. Global net product revenues for ONPATTRO rose 6% to $120 million, while GIVLAARI grew 4% to $32 million. However, OXLUMO saw a 9% decline in revenue. Alnylam reaffirmed its 2021 guidance of $640-$665 million in revenues and announced a leadership transition from CEO John Maraganore to Yvonne Greenstreet.
Alnylam Pharmaceuticals announces a leadership transition with CEO John Maraganore passing the reins to Yvonne Greenstreet by year-end 2021. Maraganore, a founding figure since 2002, has led the development of RNAi therapeutics, contributing to the approval of four medicines in 25 countries. Greenstreet, currently President and COO, brings significant experience and will step into her new role while Maraganore continues as a consultant until March 2022. The Board expressed strong confidence in Greenstreet's leadership to advance Alnylam’s P5x25 strategy.
Alnylam Pharmaceuticals announced that the HELIOS-A Phase 3 study of vutrisiran met all 18-month secondary endpoints. Significant improvements were observed in neuropathy, quality of life, gait speed, nutritional status, and overall disability compared to external placebo data. Additionally, vutrisiran showed positive exploratory endpoint results, including improved NT-proBNP levels and technetium uptake, indicating reduced cardiac amyloid burden. The drug has an encouraging safety profile, with minimal discontinuations due to adverse events. Full results are expected to be presented at an upcoming medical conference.
Alnylam Pharmaceuticals (NASDAQ: ALNY) will announce its third-quarter financial results for 2021 on October 28, 2021, before U.S. markets open. The company will host a conference call at 8:30 am ET to discuss results and future expectations. Investors can access the live call by dialing 877-312-7507 (domestic) or +1-631-813-4828 (international), with a replay available later in the day. Alnylam develops innovative RNA interference (RNAi) therapeutics aimed at addressing severe diseases, with a commitment to delivering transformative medicines through its ongoing pipeline.
Alnylam Pharmaceuticals (NASDAQ: ALNY) has launched the Alnylam Challengers program, committing $1 million to Acumen America to enhance health equity initiatives. This partnership aims to assist 75 million individuals in the U.S. by 2024 by tackling health disparities due to poverty and discrimination. The program includes a Social Investment Portfolio, an Advisory Corps for expert volunteering, and cross-sector Convenings to address health equity issues. Alnylam emphasizes its corporate responsibility and investment in sustainable health solutions.
Alnylam Pharmaceuticals announced promising pre-clinical research at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, showcasing innovations in RNAi therapeutics. Their hexadecyl (C16) conjugate demonstrates over 90% target knockdown potential in the CNS with an annual dosing regimen. The presentation also highlighted the IKARIA platform, which facilitates effective siRNA delivery. Additionally, pre-clinical data on ALN-APP for early-onset Alzheimer's Disease showed promising results, with plans for a clinical trial application later this year.